Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07736924
Starting soon Observational

2D:4D Digit Ratio and Urinary Stone Disease

NCT07736924 · tracked via the Priya Life Science Turkey tracker
Sponsor
Emrah Kızılay
Phase
Observational
Started
2026-08-01
Last updated
2026-07-30

Condition(s) studied

Urinary Stone

Study summary

This prospective observational case-control study will investigate whether the 2D:4D digit ratio is associated with urinary stone disease. Adults undergoing non-contrast computed tomography at Malatya Training and Research Hospital will be classified as cases if kidney and/or ureteral stones are detected and as controls if no urinary stones are detected and there is no previous history of stone disease or stone surgery. The lengths of the second and fourth fingers of both hands will be measured using a digital caliper by two independent observers who are blinded to the participant group. The study will also examine whether the 2D:4D ratio is associated with recurrent stone disease, stone burden, and bilateral or multiple stones.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 18 years or older * Provision of written informed consent * Undergoing non-contrast computed tomography at Malatya Training and Research Hospital during the study period * For cases: presence of at least one kidney and/or ureteral stone on non-contrast computed tomography * For controls: absence of stones in the kidneys, ureters, and bladder on non-contrast computed tomography * For controls: no previous physician-diagnosed urinary stone disease or history of stone-related surgery * Feasibility of bilateral second- and fourth-digit length measurements Exclusion Criteria: * Congenital deformity of the hands or fingers * History of hand or finger trauma, fracture, surgery, or amputation that may affect digit length measurement * Severe hand deformity, contracture, or advanced joint disease preventing reliable measurement * Incomplete, inadequate, or technically unreliable 2D:4D measurements * Missing essential clinical, demographic, or imaging data * Pregnancy * Presence of bladder stones * Urinary diversion, major urinary tract reconstruction, or a significant structural urinary tract anomaly

Primary outcome measure(s)

  • Mean Bilateral 2D:4D Digit Ratio by Urinary Stone Disease Status — At enrollment, during the single study assessment
    The lengths of the second and fourth digits of both hands will be measured using a digital caliper by two independent observers blinded to group status. Right and left 2D:4D ratios will be calculated by dividing the length of the second digit by the length of the fourth digit. The mean bilateral 2D:4D ratio will be calculated as the average of the right and left ratios and compared between participants with computed tomography-confirmed kidney and/or ureteral stones and stone-free controls.

Trial sites (1)

FacilityCityRegionStatus
Malatya Training and Research Hospital Malatya Malatya
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07736924 on ClinicalTrials.gov ↗ ← All trials in Turkey